OUR SCIENCE TELLS A STORY

Our current development portfolio contains 4 clinical candidates for which we own the worldwide rights.

• Now Approved: WINLEVI^® (clascoterone) cream 1%

  Now Approved: WINLEVI

  Treatment target

  WINLEVI is a first-in-class topical androgen receptor inhibitor approved by the US Food and Drug Administration (FDA).

  Science story

  Read the latest press release to learn more about the approval of WINLEVI and its novel mechanism of action.

  Development stage

  WINLEVI, our first-in-class topical treatment, is now approved by the FDA. WINLEVI is expected to be available in the United States sometime in 2021. Please see full Prescribing Information

• Clascoterone solution 7.5%

  CLASCOTERONE SOLUTION 7.5% FOR TREATMENT OF AGA

  Treatment target

  Clascoterone solution 7.5% is a novel AR inhibitor that targets androgen receptors in the scalp and is currently being studied for the treatment of androgenetic alopecia (AGA).

  Science story

  AGA is the most common cause of hair loss.³ AGA is driven by dihydrotestosterone (DHT). Androgens normally stimulate terminal hair production in many sites of the body, like the beard and the axillary regions, but exert an opposite effect to suppress hair growth on the genetically predisposed frontal and vertex scalp. Therefore, people with scalp hair follicles that are genetically sensitive to DHT experience progressive hair follicle miniaturization, or hair thinning, and shortening of the hair growth cycle, resulting in characteristic “male pattern baldness” or thinning hair in genetically predisposed females.
  Clascoterone solution 7.5% acts by inhibiting DHT’s binding with androgen receptors in scalp hair follicles and thus may interfere with DHT’s effect on scalp hair loss.⁴ Laboratory studies show that clascoterone solution 7.5% reduces production of inflammatory mediators involved with hair miniaturization.⁵

  Development stage

  A Phase II dose ranging study with clascoterone solution in males ended in early 2019. Clascoterone solution 7.5% was selected as the best candidate for the Phase III adult male AGA program. A Phase II study involving female AGA subjects is underway with top-line results expected 3Q 2021.

• CB-06-01

  CB-06-01

  Treatment target

  CB-06-01 is a novel topical antibiotic currently under development and investigation for acne. It is a topical antibiotic that could provide another option against Cutibacterium acnes bacteria.

  Science story

  Many C acnes strains are resistant to commonly prescribed antibiotics for acne. There is a need for a novel antibiotic treatment to help patients who suffer from acne.

  Development stage

  CB-06-01 has successfully completed a POC study and is now in formulation optimization.

• CB-06-02

  CB-06-02

  Treatment target

  CB-06-02, also referred to as AS 101, is a topical treatment for genital warts. It acts to support patients’ natural immune responses against human papillomavirus (HPV) and its warts.

  Science story

  Current topical treatments can be ineffective and frequent recurrence of genital warts can affect the sexual health of millions of patients.

  Development stage

  CB-06-02 has completed a Phase II proof-of-concept clinical trial.